在医疗服务不足的患者中实施临床药物遗传测试:叙事性审查
Brian E Gawronski1, Irina Fofanova1, Angel M Miranda1
1Department Pharmacotherapy and Translational Research and Center for Pharmacogenomics and Precision Medicine, College of Pharmacy, University of Florida, Gainesville, FL, USA.
Pharmacogenomics
|April 11, 2025
概括
药物遗传学 (PGx) 测试可以改善药物治疗,特别是在医疗服务不足的人群 (MUP) 中. 需要进一步的研究,以确定PGx测试在MUP中的可行性和有效性,以减少医疗保健差异.
科学领域:
- 药物基因组学 药物基因组学
- 健康差异 在健康上的差异
- 卫生技术实施 卫生技术实施
背景情况:
- 医疗服务不足的人群 (MUPs) 面临着减少医疗保健的机会和不同的健康结果.
- 药物遗传学 (PGx) 测试为MUP的药物管理提供了潜在的好处,因为药物不良事件和多药物的风险更高.
- 在多州医院有限地实施PGx测试可能会加剧现有的医疗保健差异.
研究的目的:
- 审查医疗服务不足对健康的影响.
- 探索PGx测试对MUP的潜在好处.
- 检查目前的研究和早期临床实施的PGx测试在MUPs.
主要方法:
- 现有文献的叙述性审查.
- 对MUP中PGx测试可接受性和感知度的研究分析.
- 评价在多国机关中对PGx测试的试点实施情况.
主要成果:
- 文献表明,MUP中的PGx测试可接受性支持实施开发.
- 已经开始进行有限的试点研究,以评估在MUP中进行PGx测试的可行性.
- 需要进一步的证据来证实MPU中PGx测试的可行性和有效性.
结论:
- 在MUP中进行广泛的PGx测试需要进一步研究可行性和有效性.
- 在MUP中成功实施PGx可以帮助缓解医疗保健差异.
- 解决PGx测试准入问题对于公平的药物治疗管理至关重要.
更多相关视频
相关概念视频
Clinical Trials: Overview
2.5K
Clinical development focuses on how the drug will interact with the human body and encompasses four key phases of clinical trials, each serving a specific purpose in assessing the safety and effectiveness of new drugs. These phases overlap and build upon one another. Phase I involves a small group of healthy volunteers (typically 20-80 individuals) or, in cases where significant toxicity is expected, patients with the targeted disease, such as cancer or AIDS. The volunteers are tested for...
2.5K
Analysis of Population Pharmacokinetic Data
202
Analysis of population pharmacokinetic data involves studying the behavior of drugs within diverse populations to understand their pharmacokinetic parameters. Traditional pharmacokinetic methods typically involve collecting samples from a few individuals and estimating these parameters. While these methods are commonly used, they have limitations in capturing the variability in drug response among individuals or heterogeneous populations. Population pharmacokinetics is employed to address these...
202


